Infantile cerebellar-retinal degeneration associated with a mutation in mitochondrial aconitase, ACO2.

Department of Pediatrics A, Ha'Emek Medical Center, Afula, Israel.
The American Journal of Human Genetics (Impact Factor: 11.2). 03/2012; 90(3):518-23. DOI: 10.1016/j.ajhg.2012.01.009
Source: PubMed

ABSTRACT Degeneration of the cerebrum, cerebellum, and retina in infancy is part of the clinical spectrum of lysosomal storage disorders, mitochondrial respiratory chain defects, carbohydrate glycosylation defects, and infantile neuroaxonal dystrophy. We studied eight individuals from two unrelated families who presented at 2-6 months of age with truncal hypotonia and athetosis, seizure disorder, and ophthalmologic abnormalities. Their course was characterized by failure to acquire developmental milestones and culminated in profound psychomotor retardation and progressive visual loss, including optic nerve and retinal atrophy. Despite their debilitating state, the disease was compatible with survival of up to 18 years. Laboratory investigations were normal, but the oxidation of glutamate by muscle mitochondria was slightly reduced. Serial brain MRI displayed progressive, prominent cerebellar atrophy accompanied by thinning of the corpus callosum, dysmyelination, and frontal and temporal cortical atrophy. Homozygosity mapping followed by whole-exome sequencing disclosed a Ser112Arg mutation in ACO2, encoding mitochondrial aconitase, a component of the Krebs cycle. Specific aconitase activity in the individuals' lymphoblasts was severely reduced. Under restrictive conditions, the mutant human ACO2 failed to complement a yeast ACO1 deletion strain, whereas the wild-type human ACO2 succeeded, indicating that this mutation is pathogenic. Thus, a defect in mitochondrial aconitase is associated with an infantile neurodegenerative disorder affecting mainly the cerebellum and retina. In the absence of noninvasive biomarkers, determination of the ACO2 sequence or of aconitase activity in lymphoblasts are warranted in similarly affected individuals, based on clinical and neuroradiologic grounds.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: The advent of whole-exome sequencing (WES) has facilitated the discovery of rare structure and functional genetic variants. Combining exome sequencing with linkage studies is one of the most efficient strategies in searching disease genes for Mendelian diseases. WES has achieved great success in the past three years for Mendelian disease genetics and has identified over 150 new Mendelian disease genes. We illustrate the workflow of exome capture and sequencing to highlight the advantages of WES. We also indicate the progress and limitations of WES that can potentially result in failure to identify disease-causing mutations in part of patients. With an affordable cost, WES is expected to become the most commonly used tool for Mendelian disease gene identification. The variants detected cumulatively from previous WES studies will be widely used in future clinical services.
    Frontiers of medicine. 01/2014;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Neuroscience Letters j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / n e u l e t Decreased expression of proteins involved in energy metabolism in the hippocampal granular layer of rats submitted to the pilocarpine epilepsy model h i g h l i g h t s • Decrease in expression of proteins involved in energy metabolism in the hippocampal granular layer. • For the first time we identify new molecular insights into the altered protein profile of the epileptogenic dentate gyrus. • The proteins described could be used as further biomarkers or therapeutic targets for epilepsy treatment. a b s t r a c t Long-term structural and functional changes in the hippocampus have been identified as the primary physiopathological basis for temporal lobe epilepsy. These changes include reactive gliosis and granule cell axonal sprouting within the dentate gyrus. The intimate mechanisms of these changes are beginning to be revealed. Here, we show the possibility of using laser capture microdissection (LCM) to isolate the dentate granular cell layer of Wistar rats submitted to the pilocarpine model of epilepsy. Using two-dimensional gel electrophoresis (2-D PAGE) and mass spectrometry for laser-captured cells, we identified molecular events that could be altered as part of the epileptic pathogenic process. According to our results, eight proteins related to energy metabolism were differentially expressed between both the control and pilocarpine-treated animals. These results provide, for the first time, new molecular insights into the altered protein profile of the epileptogenic dentate gyrus and can contribute to a better understanding of the phenomena involved in the genesis and maintenance of the epileptic state. Abbreviations: [K + ], potassium concentration; 2-D PAGE, two-dimensional gel electrophoresis; ATP, adenosine triphosphate; SUCLA2, succinyl-CoA ligase [ADP-forming] subunit beta; ACO2, aconitate hydratase; SLC25A12, calcium-binding mitochondrial carrier protein Aralar1; (GOT2), mitochondrial aspartate amino-transferase; FH1, mitochondrial fumarate hydratase; (CKB), creatine kinase B-type; Na + /K + ATPase, sodium potassium pump ATPase; NAA, N-acetyl aspartate; SE, Status Epilepticus; SRS, spontaneous recurrent seizures; LCM, laser capture microdis-section; SCOT, succinyl-CoA:3-ketoacid-coenzyme A transferase 1; HSH, human sclerotic hippocampus.
    Neuroscience Letters 12/2013; · 2.06 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Genomics has revolutionized the study of rare diseases. In this review, we overview the latest technological development, rare disease discoveries, implementation obstacles and bioethical challenges. First, we discuss the technology of genome and exome sequencing, including the different next-generation platforms and exome enrichment technologies. Second, we survey the pioneering centers and discoveries for rare diseases, including few of the research institutions that have contributed to the field, as well as an overview survey of different types of rare diseases that have had new discoveries due to next-generation sequencing. Third, we discuss the obstacles and challenges that allow for clinical implementation, including returning of results, informed consent and privacy. Last, we discuss possible outlook as clinical genomics receives wider adoption, as third-generation sequencing is coming onto the horizon, and some needs in informatics and software to further advance the field.
    Expert Review of Molecular Diagnostics 04/2014; · 4.09 Impact Factor


Available from